
# **O**TEOXANE



## THE TEOXANE APPROACH

In aesthetic medicine, most patients obtain natural-looking and balanced outcomes.<sup>4</sup>
Working with your expertise, the TEOXANE approach alllows you to tailor your technique to optimal, natural-looking and unique results, maintaining the dynamic movements of the face.

Using the right products, injected in the right area, with the correct techniques.

A TH
DIMENSION
IN FACIAL
AESTHETICS

#### **ANATOMY**

Knowledge based on anatomical layers and compartments in order to assess facial dynamics

#### **TECHNIQUE**

Use of appropriate techniques based on a detailed facial assessment

#### **PRODUCT**


Innovative and cuttingedge dermal fillers that adapt to static and dynamic facial layers

## ANATOMY & PATIENT ASSESSMENT

From the age of 30, more than 50% of women are concerned by under eye hollows.<sup>5</sup>

#### **ANATOMY ASSESSEMENT OF THE INFRAORBITAL REGION:**

Before any treatment of the infraorbital hollows, the pathways of the main vessels and nerves should be checked to ensure that the filler injection is safe.



#### TO CONSIDER

- The lymphatic system around the eye area
- The angular artery
- The emergence of the infraorbital nerve
- And also the malar ptosis due to ageing





Tear troug



Palpebromalar groove




Mid cheek

# INFRAORBITAL HOLLOWS TREATMENT

#### Literature agrees that:

66

As midface volume deficit increases, tear trough severity increases significantly. Adding volume to the midface using HA dermal filler can reduce the appearance of tear troughs. 99



Therefore, midface volume deficit is adequately treated first prior to the infraorbital hollow helping to provide a natural-looking outcome and refreshed look.

88% OF THE HEALTHCARE PROFESSIONALS INJECT THE MIDFACE AS PART OF THEIR PERIORBITAL TREATMENT PLAN.8


# A TWO-STEP APPROACH TO INFRAORBITAL AREA


A dynamic filler for soft volume enhancement in the midface<sup>9,10</sup> combined with the first & only product specifically designed to treat the under eye hollows<sup>3</sup> for a comprehensive treatment plan.<sup>11,12</sup>

# 1<sup>st</sup> INJECTION To treat the midface

In the deep, medial cheek fat compartment<sup>9,12,13</sup>


In the SOOF\* for the palpebromalar groove<sup>14</sup>





#### 2<sup>nd</sup> INJECTION To treat the under eye cavity

Deep supraperiosteal / Suborbicular injection<sup>1,3</sup>



# REDENSITY 2\*

# FIRST AND ONLY HYALURONIC ACID GEL DESIGNED FOR UNDER EYES HOLLOWS<sup>1,3</sup>



HYALURONIC ACID CONCENTRATION	15 mg/mL
COMPOSITION	A unique mixture of crosslinked & noncrosslinked HA
DEGREE OF MODIFICATION	~5%
LIDOCAINE	0.3 %
INJECTION TECHNIQUE RECOMMENDED	Supraperiosteal Deep suborbicular
NEEDLE	30G x 1/2"
PACKAGING	2 x 1 mL

#### UP TO 12 MONTHS DURATION11


66

When I choose a product, first I look at the safety.

But my second concern is that I want a product that fits really well with the area, and so I love to have a dedicated product.

Dr P. Trévidic, Plastic Surgeon, specialised in gesthetic medicine





# RHA® 4\*\*\*

# DYNAMIC & SOFT VOLUMIZING IN THE MID CHEEK



		9
HYALURONIC ACID CONCENTRATION	23 mg/mL	
COMPOSITION	High Molecular Weight Crosslinked Hyaluronic Acid	-
DEGREE OF MODIFICATION	~4%	
LIDOCAINE	0.3 %	
FOCUS INDICATIONS	Volume in extended areas Cheeks, contours of the face	
INJECTION TECHNIQUE RECOMMENDED	Subdermal & Supraperiosteal	-
NEEDLE	27 G x 1/2"	
PACKAGING	2 x 1.2 mL#	

UP TO 18 MONTHS DURATION<sup>17</sup>

Designed to provide soft volume enhancement and facial dynamism to facilitate natural-looking facial expressions. 9,10

LOW BDDE TO GET CLOSER TO NATURAL HA



## PROVEN SAFETY OVER THE YEARS


#### **REDENSITY 2 GOOD SAFETY PROFILE:18**

- Less than 2 adverse reactions per 10,000 sold syringes
- Less than 2 cases of Tyndall effect per 100,000 sold syringes
- Less than 1.5 cases of skin oedema per 10,000 sold syringes

#### SAFETY RECOGNISED IN A CLINICAL TRIAL

75% of the patients reported **no adverse event within 1 month** post-injection

Most side effects reported were mild, temporary and correctable



#### **DURING THE CLINICAL TRIAL\***

- Mainly mild and transient post-injection reactions
- No blue discoloration / Tyndall effect (after 1 month)
- No need for hyaluronidase
- No unpleasant malar swelling

Redensity 2's\*\* high malleability matches perfectly with the anatomical characteristics of the periorbital area for an easy injection, placement and molding, yielding a natural effect.

\*Multicentric and international study: 2012/2013. 33 practitioners, 151 patients (86% of women and 14% of men). Visit 1 (T0): Injection, Visit 2 (T30days): Control and evaluation. Indications: 93% of patients were injected in the tear trough area. \*\*REDENSITY 2 = TEOSYAL® PURESENSE REDENSITY 2

## PROVEN PATIENT SATISFACTION

66

A lot of my patients come to see me because they have under eye hollows that are extending into their cheek. They say that they're looking very tired, and this is where under eye hyaluronic acid fillers are so amazing, to virtually restore the under eye brightness instantly and take away the tired appearance.


99

Dr Sabrina Shah-Desai, Oculoplastic Surgeon

97 % PATIENTS SATISFIED

 $98\,\%$  would recommend the procedure

97 % WOULD REPEAT THE TREATMENT



Courtesy of Dr. Patrick TREVIDIC

2 weeks after

**Mid cheek:** Multilayering technique with TEOSYAL RHA®4\*\* (0.6 ml each side) + TEOSYAL® Ultra Deep (0.6 ml each side)

**Tear Trough:** TEOSYAL® PureSense Redensity 2 (0.5 ml each side)



Courtesy of Dr. Patrick TREVIDIC

2 weeks after

Tear trough + Palpebromalar groove with TEOSYAL® PureSense Redensity 2 (0.5 ml each side)

# EVERY PATIENT IS UNIQUE\*


#### TEAR TROUGH

#### PATIENT ASSESSMENT 19,20

- Sunken appearance of the eye globe
- Shadowing over the lower eyelid
- Fatigued appearance despite rest



INJECTION ZONE



Tear trough injection under eye cavity

# REDENSITY 2

Supraperiosteal / suborbicular injection


#### TEAR TROUGH + PALPEBROMALAR GROOVE

#### PATIENT ASSESSMENT 19,20

- Sunken appearance of the eye globe
- Shadowing over the lower eyelid
- Fatigued appearance despite rest + Depression on the lateral side



**INJECTION ZONE** 




1) Tear trough injection under eye cavity




(2) Palpebromalar groove injection

#### **REDENSITY 2**



Supraperiosteal / suborbicular injection



Medial / Lateral SOOF


#### MID CHEEK + PALPEBROMALAR GROOVE + TEAR TROUGH

#### PATIENT ASSESSMENT<sup>7,19,20</sup>

- Sunken appearance of the eye globe
- Shadowing over the lower eyelid
- Fatigued appearance despite rest
- + Midface volume deficit



INJECTION ZONE



Deep medial cheek fat compartment





Supraperiosteal /


Deep fat compartments

RHA® 4



2) Palpebromalar groove injection






3) Tear trough injection under eye cavity



Medial / Lateral SOOF





Supraperiosteal / suborbicular injection

\*Proposed treatment possibilities based on the expertise of Patrick TREVIDIC, France

# THE IDEAL COMPLEMENT TO YOUR INFRAORBITAL TREATMENT

Lightly tinted and fragance free, R[II] Eyes is a bespoke solution for the sensitive and delicate eye-contour area. Its specific and unique formula helps to visibly reduce under eye discoloration and effectively smoothen fine lines and wrinkles from the first application.



## R[II] Eyes

Dark circles – fine lines & wrinkles Suitable for sensitive skin

Unique active ingredients for immediate and long-lasting effects:

Escin and Hamamelis extracts

FRESH AND
DECONGESTING EFFECT<sup>21</sup>

RHA Resilient Hyaluronic Acid®

MAINTAINS AND PROTECTS SKIN HYDRATION LASTINGLY<sup>21</sup>

### PROVEN EFFICACY AFTER 28 DAYS<sup>22</sup>





+19%
LIGHTENING
OF DARK
CIRCLE

Photography by visia CR - TO

Photography by visia CR - T Immediate

-24%
REDUCTION IN SUPERFICIAL WRINKLES VOLUME

#### References:

- Berguiga M, Galatoire O. Tear trough rejuvenation: a safety evaluation of the treatment by a semi-crosslinked Hyaluronic Acid filler. Orbit, 2017; 36 (1):22-26.
- 2. Teoxane internal data source. TEOSYAL® PureSense Redensity 2 deliveries from 2012 to 2020: 1'011'774 boxes.
- 3. TEOSYAL® PureSense Redensity 2 instruction for use.
- 4. Michaud T, et al. J Cosmet Dermatol. 2015; 14(1): 9-21.
- 5. Arcane Research Study conducted in France in March 2018 on 8.646 women from 18 to 75 y/o.
- 6. Bravo et al. J Clin Aesthet Dermatol, 2015; 8(6):30-35.
- 7. Glaser et al. Dermatol Surg 2018; 44:1547-1554.
- 8. TEOXANE Worldwide Survey "Periorbital Treatments in Clinics by 180 injectors", June 2020.
- 9. TEOSYAL RHA® 4 instruction for use.
- 10. Data on file. TEOSYAL® RHA keeps its mechanical properties on a large range of strain or stress constraints Report Rheological characterizations of hyaluronic acid gels.
- 11. Teoxane Post Market Surveillance data November 2020. 1445 practitioners worldwide.
- 12. Ramanadham R. & Rohrich R. Plast Reconstr Surg. 2015; 136:49S-55S.
- 13. Cotofana S. et al. Facial Plast Surg. 2016; 32:253-260.
- 14. Lemaire. E2e Medical Publishing, Master Collection 2, Paris, 2011.
- 15. Data on File. Torsion and compression tests assessed on a rheometer. The measurement of the rheological parameter Delta index represents the balance between gel viscosity and elasticity. Physical analysis of HA fillers intended for infraorbital uses. RDRE 2023.
- 16. Syneos study report 7010664.SA.259.
- 17. Rzany B, et al. Dermatol Surg. 2019;45(10):1304-1314.
- 18. Teoxane Post Marketing Surveillance from 2016 to 2020-Q3.
- 19. Sharad. J Cutan Aesthet Surg. 2012;5:229238.
- 20. Sadick et al. Cosmet Dermatol. 2007 Dec;6(4):218-22.
- 21. The properties of ingredients derive from data communicated by the raw material manufacturers.
- 22. Efficacy study on 24 volunteers over 28 days.

TEOSYAL® PureSense Redensity 2 and TEOSYAL RHA® 4 are trademark of the firm TEOXANE SA. These products are gels that contain hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride (local anesthetic can induce a positive reaction to anti-doping tests). In the case of known hypersensitivity to lidocaine and/ or amide local anaesthetic agents, we recommend not use lidocaine-containing products and please refer to products without lidocaine. TEOSYAL® PureSense Redensity 2 and TEOSYAL RHA® 4 are class III medical devices and are regulated health product bearing the CE marking (CE2797) under this regulation. For professional use only. Please refer to instructions for use. These products availability depend on registration, please contact your local distributor. Please inform the manufacturer TEOXANE of any side effects or any complaint as soon as possible to the following address: medical@leoxane.com.





In today's world, beauty is no longer a question of age. Women want their beauty to last into the future and to reflect their personalities.

At TEOXANE Laboratories our focus has always been to be the global expert in the development of hyaluronic acids – keeping innovation, quality and safety at the heart of everything we do!

Valérie Taupin CEO & Founder, TEOXANE

Join our online learning platform TEOXANE ACADEMY DIGITAL to learn more.

Visit www.teoxane.academy to register